These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

419 related items for PubMed ID: 10792983

  • 1. Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes.
    Roden RB, Yutzy WH, Fallon R, Inglis S, Lowy DR, Schiller JT.
    Virology; 2000 May 10; 270(2):254-7. PubMed ID: 10792983
    [Abstract] [Full Text] [Related]

  • 2. Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region.
    Kondo K, Ishii Y, Ochi H, Matsumoto T, Yoshikawa H, Kanda T.
    Virology; 2007 Feb 20; 358(2):266-72. PubMed ID: 17010405
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Chapter 12: Prophylactic HPV vaccines: underlying mechanisms.
    Stanley M, Lowy DR, Frazer I.
    Vaccine; 2006 Aug 31; 24 Suppl 3():S3/106-13. PubMed ID: 16949996
    [Abstract] [Full Text] [Related]

  • 5. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
    Boxus M, Fochesato M, Miseur A, Mertens E, Dendouga N, Brendle S, Balogh KK, Christensen ND, Giannini SL.
    J Virol; 2016 Jul 15; 90(14):6314-25. PubMed ID: 27147749
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Developments in L2-based human papillomavirus (HPV) vaccines.
    Schellenbacher C, Roden RBS, Kirnbauer R.
    Virus Res; 2017 Mar 02; 231():166-175. PubMed ID: 27889616
    [Abstract] [Full Text] [Related]

  • 8. Minor Capsid Protein L2 Polytope Induces Broad Protection against Oncogenic and Mucosal Human Papillomaviruses.
    Pouyanfard S, Spagnoli G, Bulli L, Balz K, Yang F, Odenwald C, Seitz H, Mariz FC, Bolchi A, Ottonello S, Müller M.
    J Virol; 2018 Feb 15; 92(4):. PubMed ID: 29212932
    [Abstract] [Full Text] [Related]

  • 9. Mucosal vaccination with a recombinant Salmonella typhimurium expressing human papillomavirus type 16 (HPV16) L1 virus-like particles (VLPs) or HPV16 VLPs purified from insect cells inhibits the growth of HPV16-expressing tumor cells in mice.
    Revaz V, Benyacoub J, Kast WM, Schiller JT, De Grandi P, Nardelli-Haefliger D.
    Virology; 2001 Jan 05; 279(1):354-60. PubMed ID: 11145916
    [Abstract] [Full Text] [Related]

  • 10. Role of conformational epitopes expressed by human papillomavirus major capsid proteins in the serologic detection of infection and prophylactic vaccination.
    Hines JF, Ghim SJ, Christensen ND, Kreider JW, Barnes WA, Schlegel R, Jenson AB.
    Gynecol Oncol; 1994 Oct 05; 55(1):13-20. PubMed ID: 7525426
    [Abstract] [Full Text] [Related]

  • 11. Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes.
    Kondo K, Ochi H, Matsumoto T, Yoshikawa H, Kanda T.
    J Med Virol; 2008 May 05; 80(5):841-6. PubMed ID: 18360909
    [Abstract] [Full Text] [Related]

  • 12. Human papillomavirus vaccine development.
    Fife KH.
    Australas J Dermatol; 1998 Nov 05; 39 Suppl 1():S8-10. PubMed ID: 9842094
    [Abstract] [Full Text] [Related]

  • 13. Human papillomavirus vaccines.
    Breitburd F, Coursaget P.
    Semin Cancer Biol; 1999 Dec 05; 9(6):431-44. PubMed ID: 10712890
    [Abstract] [Full Text] [Related]

  • 14. Nasal immunization of mice with peptide having a cross-neutralization epitope on minor capsid protein L2 of human papillomavirus type 16 elicit systemic and mucosal antibodies.
    Kawana K, Kawana Y, Yoshikawa H, Taketani Y, Yoshiike K, Kanda T.
    Vaccine; 2001 Jan 08; 19(11-12):1496-502. PubMed ID: 11163673
    [Abstract] [Full Text] [Related]

  • 15. Natural variants in the major neutralizing epitope of human papillomavirus minor capsid protein L2.
    Seitz H, Schmitt M, Böhmer G, Kopp-Schneider A, Müller M.
    Int J Cancer; 2013 Feb 01; 132(3):E139-48. PubMed ID: 22961598
    [Abstract] [Full Text] [Related]

  • 16. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization.
    Kirnbauer R, Chandrachud LM, O'Neil BW, Wagner ER, Grindlay GJ, Armstrong A, McGarvie GM, Schiller JT, Lowy DR, Campo MS.
    Virology; 1996 May 01; 219(1):37-44. PubMed ID: 8623552
    [Abstract] [Full Text] [Related]

  • 17. Incorporation of RG1 epitope concatemers into a self-adjuvanting Flagellin-L2 vaccine broaden durable protection against cutaneous challenge with diverse human papillomavirus genotypes.
    Kalnin K, Chivukula S, Tibbitts T, Yan Y, Stegalkina S, Shen L, Cieszynski J, Costa V, Sabharwal R, Anderson SF, Christensen N, Jagu S, Roden RBS, Kleanthous H.
    Vaccine; 2017 Sep 05; 35(37):4942-4951. PubMed ID: 28778613
    [Abstract] [Full Text] [Related]

  • 18. Vaccines for the prevention of human papillomavirus and associated gynecologic diseases: a review.
    Ault KA.
    Obstet Gynecol Surv; 2006 Jun 05; 61(6 Suppl 1):S26-31. PubMed ID: 16729901
    [Abstract] [Full Text] [Related]

  • 19. Immunobiology of human papillomavirus infection and vaccination - implications for second generation vaccines.
    Stanley M, Gissmann L, Nardelli-Haefliger D.
    Vaccine; 2008 Aug 19; 26 Suppl 10():K62-7. PubMed ID: 18847558
    [Abstract] [Full Text] [Related]

  • 20. A peptide encoding a B-cell epitope from the N-terminus of the capsid protein L2 of bovine papillomavirus-4 prevents disease.
    Campo MS, O'Neil BW, Grindlay GJ, Curtis F, Knowles G, Chandrachud L.
    Virology; 1997 Aug 04; 234(2):261-6. PubMed ID: 9268157
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.